Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 21 |
| Active Pipeline (Recruiting Now) | 13 (5) |
| Completed vs Stopped Early | 2 / 2 (9.5%) |
| Median Closed Actual Enrollment | 110 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Tianjin Medical University General Hospital | Tianjin, Tianjin Municipality | 15 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT06452537 | Safety and Efficacy of Tocilizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease | Phase II/III | ACTIVE NOT RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the Tianjin Medical University General Hospital Interactive Dossier, benchmark peers in Rare Genetic, Women's Health, and Other, or review the Healthcare Price & Patent Cliff Crosswalk.